MX338940B - Identificacion de epitopos ige novedosos. - Google Patents

Identificacion de epitopos ige novedosos.

Info

Publication number
MX338940B
MX338940B MX2011007343A MX2011007343A MX338940B MX 338940 B MX338940 B MX 338940B MX 2011007343 A MX2011007343 A MX 2011007343A MX 2011007343 A MX2011007343 A MX 2011007343A MX 338940 B MX338940 B MX 338940B
Authority
MX
Mexico
Prior art keywords
ige
subject
high affinity
identification
novel
Prior art date
Application number
MX2011007343A
Other languages
English (en)
Inventor
Sanjaya Singh
Danyang Huang
Sek Chung Michael Fung
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX338940B publication Critical patent/MX338940B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • General Physics & Mathematics (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Otolaryngology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a un anticuerpo aislado o un fragmento que se une al antígeno del mismo, que comprende una región variable de cadena liviana que comprende CDRL1, CDRL2 y CDRL3 y una región variable de cadena pesada que comprende CDRH1, CDRH2 y CDRH3, en donde CDRL1consiste de la SEQ ID NO: 5, CDRL2 consiste de la SEQ ID NO: 6, CDRL3 consiste de la SEQ ID NO: 78, CDRH1 consiste de la SEQ ID NO: 15, CDRH2 consiste de la SEQ ID NO: 25 y CDRH3 consiste de la SEQ ID NO: 26, en donde el anticuerpo se une específicamente a IgE.
MX2011007343A 2003-02-01 2004-07-29 Identificacion de epitopos ige novedosos. MX338940B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US44422903P 2003-02-01 2003-02-01
PCT/US2004/002894 WO2004070011A2 (en) 2003-02-01 2004-02-02 HIGH AFFINITY ANTI-HUMAN IgE ANTIBODIES
PCT/US2004/002892 WO2004070010A2 (en) 2003-02-01 2004-02-02 A method for generating high affinity antibodies

Publications (1)

Publication Number Publication Date
MX338940B true MX338940B (es) 2016-05-06

Family

ID=32850839

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011007343A MX338940B (es) 2003-02-01 2004-07-29 Identificacion de epitopos ige novedosos.

Country Status (15)

Country Link
US (4) US7531169B2 (es)
EP (4) EP1592777A4 (es)
JP (4) JP2006516408A (es)
CN (3) CN102993306B (es)
AU (3) AU2004209638B2 (es)
CA (2) CA2514839A1 (es)
CY (2) CY1118063T1 (es)
DK (2) DK2407485T3 (es)
ES (2) ES2566778T3 (es)
HU (2) HUE028407T2 (es)
IL (1) IL176940A (es)
MX (1) MX338940B (es)
PT (1) PT2000481E (es)
SI (2) SI2000481T1 (es)
WO (2) WO2004070010A2 (es)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
EP1592777A4 (en) * 2003-02-01 2008-06-04 Tanox Inc METHOD OF GENERATING HIGH-ANTIBODY ANTIBODIES
WO2005075504A1 (en) * 2004-02-02 2005-08-18 Tanox, Inc. IDENTIFICATION OF NOVEL IgE EPITOPES
US20060234296A1 (en) * 2003-02-01 2006-10-19 Sanjaya Singh Method for generating high affinity antibodies
JP4943161B2 (ja) 2003-12-23 2012-05-30 ジェネンテック， インコーポレイテッド 新規抗ｉｌ１３モノクローナル抗体での癌の処置
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
WO2006055704A2 (en) * 2004-11-17 2006-05-26 Curagen Corporation Antibodies directed to ten-m proteins and uses thereof
EP1941275B1 (en) * 2005-09-29 2013-07-24 Medimmune, Inc. Method of identifying membrane lg specific antibodies and use thereof for targeting immunoglobulin-producing precursor cells
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
AR065368A1 (es) 2007-02-15 2009-06-03 Astrazeneca Ab Anticuerpos para moleculas de ige
SI2132230T1 (sl) 2007-03-22 2014-07-31 Genentech, Inc. Apoptotska protitelesa, ki veĹľejo membransko-vezan IgE
DE102007052281A1 (de) * 2007-11-02 2009-05-07 Zenteris Gmbh Einschritt-Multiplex-Immuntest
EP2221384A4 (en) 2007-12-03 2011-04-06 Advance Kk METHOD FOR MANUFACTURING ANTIBODY
US20130338038A1 (en) 2007-12-21 2013-12-19 Pdl Biopharma, Inc. Method of screening complex protein libraries to identify altered properties
CN101230103B (zh) * 2008-03-25 2011-09-07 中国医药集团总公司四川抗菌素工业研究所 一全人源重组抗-IgE抗体
JP5785493B2 (ja) 2008-09-17 2015-09-30 ゼンコア インコーポレイテッド ＩｇＥ媒介性疾患を治療するための新規組成物および方法
ES2615881T3 (es) 2009-05-07 2017-06-08 Stallergenes Uso de inmunoglobulinas igg1 y/o de ligandos del receptor cd32 para el tratamiento de enfermedades y manifestaciones inflamatorias por vía mucosa.
JP6139885B2 (ja) 2009-10-26 2017-05-31 ジェネンテック， インコーポレイテッド 治療的抗ＩｇＥ抗体に特異的な抗体を検出するためのアッセイ及びアナフィラキシーにおけるそれらの使用
PH12012501991A1 (en) * 2010-04-07 2017-07-26 Abbvie Inc Tnf-alpha binding proteins
WO2013096791A1 (en) 2011-12-23 2013-06-27 Genentech, Inc. Process for making high concentration protein formulations
US20130243750A1 (en) 2012-01-31 2013-09-19 Genentech, Inc. Anti-ige antibodies and methods using same
PL2849723T3 (pl) 2012-05-18 2018-10-31 Genentech, Inc. Formulacje o wysokim stężeniu przeciwciał monoklonalnych
IL312711A (en) 2012-08-21 2024-07-01 Regeneron Pharma Methods for the treatment or prevention of asthma through the administration of an antagonist to 4R-IL
KR102576903B1 (ko) 2012-09-07 2023-09-13 리제너론 파아마슈티컬스, 인크. Ｉｌ-4ｒ 길항제 투여로 아토피성 피부염을 치료하는 방법
TWI755763B (zh) 2013-06-04 2022-02-21 美商再生元醫藥公司 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
TWI634900B (zh) 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
US10196458B2 (en) 2013-07-26 2019-02-05 The Regents Of The University Of California Anti-immunoglobulin E antibodies and methods of using thereof
WO2015114056A1 (en) 2014-01-29 2015-08-06 Ge Healthcare Bio-Sciences Ab Method and system for interaction analysis
KR102927870B1 (ko) 2014-02-28 2026-02-19 리제너론 파아마슈티컬스, 인크. Ｉｌ-4ｒ 길항제의 투여에 의한 피부 감염의 치료 방법
CN106573972B (zh) * 2014-06-17 2021-04-06 中央研究院 交联B淋巴细胞的CD23但不致敏肥大细胞的人源化抗-IgE抗体
CA2960445A1 (en) * 2014-10-24 2016-04-28 F.Hoffmann-La Roche Ag Vh-vl-interdomain angle based antibody humanization
WO2016077675A1 (en) 2014-11-14 2016-05-19 Sanofi Biotechnology Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist
US11771743B2 (en) 2016-09-01 2023-10-03 Regeneron Pharmaceuticals, Inc. Methods for preventing or treating allergy by administering an IL-4R antagonist
US10485844B2 (en) 2016-09-22 2019-11-26 Regeneron Pharmaceuticals, Inc. Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor
TWI857389B (zh) 2016-12-01 2024-10-01 美商再生元醫藥公司 治療發炎症狀的方法
KR102579836B1 (ko) 2016-12-22 2023-09-15 제넨테크, 인크. 동결건조된 폴리펩타이드의 재구성 시간을 감소시키기 위한 방법 및 제제
EP3565587A4 (en) * 2017-01-06 2020-12-16 The Regents of The University of California THERAPEUTIC ANTI-IGE ANTIBODIES AND RELATED METHODS AND COMPOSITIONS
WO2019028367A1 (en) 2017-08-04 2019-02-07 Regeneron Pharmaceuticals, Inc. METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES
EP3703818B1 (en) 2017-10-30 2023-11-01 Sanofi Biotechnology Il-4r antagonist for use in a method for treating or preventing asthma
KR20230142806A (ko) 2018-02-09 2023-10-11 제넨테크, 인크. 비만 세포 매개 염증성 질환에 대한 치료 및 진단 방법
JP7589045B2 (ja) * 2018-03-26 2024-11-25 ノバルティス アーゲー リゲリズマブを使用して慢性特発性蕁麻疹を治療する方法
MA52624A (fr) 2018-05-13 2021-03-24 Regeneron Pharma Méthodes de traitement de la dermatite atopique par administration d'un inhibiteur de l'il-4r
CN109651510B (zh) * 2018-12-04 2023-03-24 上海长征医院 抗Eno1抗体及其用途
SG11202109002XA (en) 2019-03-21 2021-09-29 Regeneron Pharma Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy
GB2589049C (en) 2019-04-11 2024-02-21 argenx BV Anti-IgE antibodies
CA3147436A1 (en) 2019-07-16 2021-01-21 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4r antagonist
AU2020325021B2 (en) 2019-08-05 2024-05-30 Regeneron Pharmaceuticals, Inc. Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R antagonist
EP4010373A1 (en) 2019-08-05 2022-06-15 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r antagonist
JP2021141861A (ja) * 2020-03-13 2021-09-24 富士フイルム和光純薬株式会社 抗原に対する親和力が向上した抗体のスクリーニング方法および製造方法
WO2021255621A1 (en) 2020-06-15 2021-12-23 Novartis Ag Treatment of food allergy using anti-ige antibodies
JP2024509971A (ja) 2021-03-11 2024-03-05 アイジェニックス， インコーポレイテッド アレルギー応答を予測するための方法およびシステム
CN117460531A (zh) 2021-06-14 2024-01-26 诺华股份有限公司 含有抗IgE抗体的药物配制品
EP4431528A1 (en) * 2021-10-29 2024-09-18 Longbio Pharma (Suzhou) Co., Ltd. Isolated antigen binding protein and use thereof
KR20240116810A (ko) 2021-12-14 2024-07-30 노파르티스 아게 항-ige 항체를 사용한 알레르기 반응의 치료
CN116143932B (zh) * 2022-12-07 2025-02-11 南开大学 一种针对IgE的抗体或其抗原结合片段以及Fc变体
CN116359516A (zh) * 2023-04-04 2023-06-30 郑州安图生物工程股份有限公司 检测血清总IgE含量的试剂盒及应用
CN119490594B (zh) * 2023-08-15 2025-09-16 东莞市朋志生物科技有限公司 一种抗免疫球蛋白e的抗体及其应用
CN119745868B (zh) * 2024-11-21 2026-04-07 广州创瑞健康科技有限公司 一种人免疫球蛋白e拮抗剂、筛选方法以及应用

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1268176A (en) * 1916-11-29 1918-06-04 Us Slicing Machine Co Power mechanism for slicing-machines.
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5428133A (en) 1987-12-31 1995-06-27 Tanox Biosystems, Inc. Chimeric anti-human IgE-monoclonal antibody which binds to secreted IgE and membrane-bound IgE expressed by IgE-expressing B cells but notto IgE bound to FC receptors on basophils
DE122006000007I2 (de) 1987-12-31 2008-03-27 Tanox Inc -tragenden b-lymphocyten befinden.
US5091313A (en) 1988-08-05 1992-02-25 Tanox Biosystems, Inc. Antigenic epitopes of IgE present on B cell but not basophil surface
US5449760A (en) 1987-12-31 1995-09-12 Tanox Biosystems, Inc. Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or basophils
US5614611A (en) 1987-12-31 1997-03-25 Tanox Biosystems, Inc. Humanized monoclonal antibodies binding to IgE-bearing B cells but not basophils
US6048728A (en) 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
IL94611A (en) 1989-06-05 1994-12-29 Organogenesis Inc Medium for cell cultures containing insulin or growth factor similar to insulin, transferrin or iron ion, triiodothyronine or thyroxine and method of use
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
ES2113940T3 (es) * 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
WO1992017207A1 (en) * 1991-03-26 1992-10-15 Tanox Biosystems, Inc. MONOCLONAL ANTIBODIES WHICH BIND TO SECRETED AND MEMBRANE-BOUND IgE, BUT NOT TO IgE ON BASOPHILS
WO1993016185A2 (en) 1992-02-06 1993-08-19 Creative Biomolecules, Inc. Biosynthetic binding protein for cancer marker
AU687755B2 (en) 1992-08-21 1998-03-05 Genentech Inc. Method for treating an LFA-1-mediated disorder
PT589840E (pt) * 1992-09-24 2004-08-31 Tanox Biosystems Inc Anticorpos monoclonais reformulados contra um isotipo de imunoglobulina
US6066718A (en) * 1992-09-25 2000-05-23 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
US5958708A (en) * 1992-09-25 1999-09-28 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
DE69303494T2 (de) 1992-11-13 1997-01-16 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US6172213B1 (en) * 1997-07-02 2001-01-09 Genentech, Inc. Anti-IgE antibodies and method of improving polypeptides
US5994511A (en) * 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
CN1289253A (zh) * 1998-01-29 2001-03-28 泰诺士公司 以lgE拮抗剂治疗特应性皮炎
US6299875B1 (en) 1998-06-04 2001-10-09 Panacea Pharmaceuticals, Llc Methods to block IGE binding to cell surface receptors of mast cells
EP1592777A4 (en) * 2003-02-01 2008-06-04 Tanox Inc METHOD OF GENERATING HIGH-ANTIBODY ANTIBODIES
US20050169909A1 (en) 2004-02-02 2005-08-04 Sanjaya Singh Identification of novel IgE epitopes
US20060234296A1 (en) 2003-02-01 2006-10-19 Sanjaya Singh Method for generating high affinity antibodies

Also Published As

Publication number Publication date
DK2000481T3 (en) 2016-06-06
EP1592776A2 (en) 2005-11-09
CN102993306B (zh) 2015-01-28
CY1118063T1 (el) 2017-06-28
CN1771338A (zh) 2006-05-10
AU2011202021A1 (en) 2011-05-26
EP1592776A4 (en) 2008-06-04
WO2004070011A2 (en) 2004-08-19
CA2514840C (en) 2017-11-07
IL176940A (en) 2015-11-30
WO2004070010A2 (en) 2004-08-19
US20060251644A1 (en) 2006-11-09
AU2004209638B2 (en) 2011-02-03
CY1117617T1 (el) 2017-04-26
EP2407485A1 (en) 2012-01-18
HUE028407T2 (hu) 2016-12-28
US8252284B2 (en) 2012-08-28
US20140295494A1 (en) 2014-10-02
JP2006516409A (ja) 2006-07-06
WO2004070011A3 (en) 2005-11-24
EP1592777A4 (en) 2008-06-04
JP4764334B2 (ja) 2011-08-31
JP2011042654A (ja) 2011-03-03
US8604171B2 (en) 2013-12-10
DK2407485T3 (en) 2016-03-21
JP2011217747A (ja) 2011-11-04
EP2000481B1 (en) 2016-03-30
HK1085771A1 (en) 2006-09-01
WO2004070010A3 (en) 2005-12-08
ES2575547T3 (es) 2016-06-29
CN1771338B (zh) 2012-10-17
HK1126788A1 (en) 2009-09-11
HUE028458T2 (en) 2016-12-28
PT2000481E (pt) 2016-06-17
HK1166330A1 (en) 2012-10-26
EP2000481A1 (en) 2008-12-10
SI2407485T1 (sl) 2016-09-30
AU2004209637A1 (en) 2004-08-19
US7531169B2 (en) 2009-05-12
ES2566778T3 (es) 2016-04-15
US20110064725A1 (en) 2011-03-17
EP2407485B1 (en) 2016-01-27
SI2000481T1 (sl) 2016-08-31
CN1829806A (zh) 2006-09-06
US20130052202A1 (en) 2013-02-28
JP5296138B2 (ja) 2013-09-25
IL176940A0 (en) 2006-12-10
US9156908B2 (en) 2015-10-13
CN102993306A (zh) 2013-03-27
AU2011202021B2 (en) 2013-08-29
CA2514839A1 (en) 2004-08-19
CA2514840A1 (en) 2004-08-19
JP2006516408A (ja) 2006-07-06
AU2004209638A1 (en) 2004-08-19
EP1592777A2 (en) 2005-11-09

Similar Documents

Publication Publication Date Title
EA200800812A1 (ru) Композиции антитела против cd3
EA200801735A1 (ru) Антиамилоидные иммуногенные композиции, способы и применения
CY1120249T1 (el) Αντισωμα ανταγωνιστης κατευθυνομενο εναντι πεπτιδιου σχετιζομενου με το γονιδιο καλσιτονινης
EA201490677A1 (ru) Связывающие антиген cd27l белки
EA201070539A1 (ru) НОВЫЕ АНТИТЕЛА, СПЕЦИФИЧНЫЕ К β-АМИЛОИДНЫМ ПЕПТИДАМ, И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ДИАГНОСТИЧЕСКИХ ИЛИ ЛЕКАРСТВЕННЫХ СРЕДСТВ
EA201000207A1 (ru) Новые иммуногенные эпитопы для иммунотерапии
CY1116632T1 (el) Εξουδετερωτες αντισωματων του τελεστη διεγερσης αποικιων κοκκιοκυτταρων μακροφαγων ανθρωπου
EA200700136A1 (ru) Анти-cd154-антитела
ATE552276T1 (de) Modifizierter anti-cd52-antikörper
EA200700751A1 (ru) Способы и композиции для улучшения продуцирования рекомбинантного белка
EA200701305A1 (ru) Иммуногенные композиции, содержащие циклические пептиды, полученные из бета-амилоидного пептида
TW200510459A (en) RG1 antibodies and uses thereof
MX2009008230A (es) Epitopes de celulas t reguladoras, composiciones y usos para los mismos.
EA200600390A1 (ru) Химерные антигены для нарушения толерантности хозяина к чужеродным антигенам
WO2006009920A3 (en) Epitope analogs
DE602006006200D1 (de) Antikörper gegen 25-hydroxyvitamin d
WO2005000901A3 (en) Cd20-specific antibodies and methods of employing same
EA201100070A1 (ru) Туберкулезный белок rv2386c, композиции и их применения
MX341536B (es) Epitopo y anticuerpos beta amiloide de oligomero especifico.
WO2006085967A3 (en) OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
WO2008098917A3 (en) Novel antibodies against igf-ir
EA201491851A1 (ru) Композиции и способы для лечения болезни альцгеймера
EA201100071A1 (ru) Новые композиции и способы
ATE338772T1 (de) Peptide gegen dcm hervorrufende autoantikörper
FR2968303B1 (fr) Peptides modulateurs du complexe saspase-flg2